Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine"
DOI: 10.1007/s12020-021-02915-7
Abstract: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a gastrinoma. Gastrinoma treatment has two goals: the control of acid hypersecretion and the control of tumor growth. While therapy for the… read more here.
Keywords: syndrome zes; somatostatin analogs; ssas; ellison syndrome ... See more keywords
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01600-x
Abstract: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate… read more here.
Keywords: first generation; somatostatin analogs; treatment; generation ... See more keywords
Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1391217
Abstract: ABSTRACT Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs;… read more here.
Keywords: somatostatin analogs; treatment neuroendocrine; analogs treatment; neuroendocrine tumors ... See more keywords
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review
Sign Up to like & getrecommendations! Published in 2020 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000001198
Abstract: Background/objective Data regarding the nephrotoxicity of the peptide receptor radionuclide therapy (PRRT) with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs (RSA) are inconclusive. We aimed to evaluate the short- and long-term nephrotoxicity following PRRT usage in patients… read more here.
Keywords: therapy; radiolabeled somatostatin; nephrotoxicity; somatostatin analogs ... See more keywords
A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada
Sign Up to like & getrecommendations! Published in 2022 at "Pancreas"
DOI: 10.1097/mpa.0000000000002144
Abstract: Objectives Somatostatin analogs (SSAs; lanreotide autogel and octreotide long-acting release) are used to treat neuroendocrine tumors; however, factors that influence SSA use are unclear. Methods This real-world, observational study collected data from private/public pharmacy claims… read more here.
Keywords: long acting; somatostatin analogs; neuroendocrine tumors; real world ... See more keywords
Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "United European Gastroenterology Journal"
DOI: 10.1177/2050640619890465
Abstract: Background Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear. We performed a… read more here.
Keywords: somatostatin analogs; response; gastric neuroendocrine; somatostatin ... See more keywords
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
Sign Up to like & getrecommendations! Published in 2019 at "BMC Cancer"
DOI: 10.1186/s12885-019-5794-y
Abstract: BackgroundDistant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim… read more here.
Keywords: somatostatin analogs; treatment; neuroendocrine tumors; micro rna ... See more keywords
Association between duration of somatostatin analogs (SSAs) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e15693
Abstract: e15693Background: Carcinoid syndrome (CS) results from the secretion of bioactive amines by functional neuroendocrine tumors. The only FDA-approved agents to treat carcinoid syndrome symptoms (CSS)... read more here.
Keywords: somatostatin analogs; ssas use; carcinoid syndrome; analogs ssas ... See more keywords
Comparison between somatostatin analog injections.
Sign Up to like & getrecommendations! Published in 2022 at "Revista da Associacao Medica Brasileira"
DOI: 10.1590/1806-9282.20211224
Abstract: OBJECTIVE Long-acting depot formulations of somatostatin analogs, i.e., octreotide and lanreotide, are the first-line medical therapies for patients with acromegaly to whom surgery/radiotherapy cannot be performed or who have inadequate response. In this study, we… read more here.
Keywords: analogs injections; somatostatin analogs; site pain; pain ... See more keywords
Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2021.625312
Abstract: Neuroendocrine tumors overexpress somatostatin receptors, which serve as important and unique therapeutic targets for well-differentiated advanced disease. This overexpression is a well-established finding in gastroenteropancreatic neuroendocrine tumors which has guided new medical therapies in the… read more here.
Keywords: medicine; somatostatin analogs; somatostatin receptors; neuroendocrine tumors ... See more keywords
Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2021.669484
Abstract: Objective Antiproliferative activity of somatostatin analogs (SSAs) has been demonstrated in digestive neuroendocrine tumors (NETs), but few data have been published in patients with pulmonary NETs. We therefore conducted a retrospective study to provide additional… read more here.
Keywords: somatostatin analogs; line; first line; metastatic lung ... See more keywords